Evidence map›Paper›PMID 30301699›Full record

ArticleUrologic oncology2018

Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma.

Davide Bimbatti, Chiara Ciccarese, Emanuela Fantinel, Teodoro Sava, Francesco Massari, Iolanda Bisogno, Mario Romano, Antonio Porcaro, Matteo Brunelli, Guido Martignoni and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Urologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Active Surveillance in Metastatic Renal Cell Carcinoma.Journal of kidney cancer and VHL · 2024
    Review
  4. Review
  5. Observational
  6. [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Davide BimbattiMedical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Chiara CiccareseMedical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Emanuela FantinelMedical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Teodoro SavaDepartment of Oncology, Camposampiero-Cittadella, Padua, Italy.
Francesco MassariDivision of Oncology, Sant'Orsola-Malpighi Hospital, Bologna, Italy.
Iolanda BisognoMedical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Mario RomanoRadiotherapy Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Antonio PorcaroUrology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Matteo BrunelliDepartment of Diagnostics and Public Health, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Guido MartignoniDepartment of Diagnostics and Public Health, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Renzo MazzarottoRadiotherapy Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Walter ArtibaniUrology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Giampaolo TortoraMedical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; U.O.C. Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
Roberto IacovelliMedical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; U.O.C. Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy. Electronic address: roberto.iacovelli@aovr.veneto.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite important results achieved for metastatic renal cell carcinoma, some patients could benefit from local treatments or an initial active surveillance (AS) period for recurrent disease. We aim to analyze: changes in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk class, the number of metastases and the disease burden from the start of AS to the beginning of systemic therapy; and if these changes influenced patient outcomes. PATIENTS AND

methodsPatients who started AS at our institution from January 2007 to April 2016 were included. The Kaplan-Meier method was used to estimate total overall survival (tOS) and progression-free survival. Changes in IMDC class, number of metastatic sites, and tumor burden (TB) were evaluated and related to patient survival. Among the patients who started active treatment, progression-free survival and post surveillance OS (psOS) were evaluated.

results52 patients were included in the analysis. Median time on AS and tOS were 18.3 and 80.1 months respectively. Baseline factors were not related to the time on AS apart from the IMDC classification (HR = 2.15; 95% CI: 1.19-3.87; P = 0.011). The increase in the number of metastatic sites during AS was correlated with poor tOS (HR = 2.86; 95% CI: 1.29-6.34; P = 0.010). The increase of the TB was a negative prognosis factor for tOS (HR = 1.16; 95% CI: 1.02-1.31; P = 0.024) and psOS (HR = 1.21; 95% CI: 1.07-1.40; P = 0.004). Both IMDC class and change in the TB at the start of therapy were related to psOS. The retrospective nature and the lack of an external review of the imaging are its main limitations.

conclusionsDuring AS, patients rarely experience a deterioration of their IMDC prognostic class, and the change in the TB, more than the increase in the number of metastatic sites, may help physicians to make decisions about the early termination of AS and the start of systemic therapy.

Indexed as

Population SurveillanceTumor BurdenAgedCarcinoma, Renal CellFemaleFollow-Up StudiesHumansKidney NeoplasmsLymphatic MetastasisMalePredictive Value of TestsRetrospective StudiesSurvival RateActive surveillanceIMDCmRCCNumber of metastatic sitesPrognosisTumor burden

Identifiers

PMID30301699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.